CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-04-20 | Woiwode Thomas Director | Other disposition | −92,918 | 0 | ||
| 2018-04-20 | Woiwode Thomas Director | Other acquisition | +2,323 | 7,282 | ||
| 2018-04-20 | Bolzon Bradley J PhD Director | Other disposition | −497,053 | 2,238,979 | ||
| 2018-04-20 | Bolzon Bradley J PhD Director | Other disposition | −2,947 | 13,277 | ||
| 2018-04-20 | Bolzon Bradley J PhD Director | Other acquisition | +92,918 | 92,918 | ||
| 2018-04-20 | Bolzon Bradley J PhD Director | Other disposition | −92,918 | 0 | ||
| 2018-04-20 | Bolzon Bradley J PhD Director | Other acquisition | +16,262 | 43,986 | ||
| 2018-04-16 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | −75,000 | 150,000 | ||
| 2018-03-07 | Ho Tony W See Remarks | Grant or award · Stock Option (Right to Buy) | +53,000 | 53,000 | ||
| 2018-03-07 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +136,000 | 136,000 | ||
| 2018-03-07 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-03-07 | TOMSICEK MICHAEL JOHN Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −45,000 | $28.00 | $1.3M | 25,204 |
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Option exercise | +1,110 | $12.57 | $14K | 26,314 |
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −1,110 | $28.24 | $31K | 25,204 |
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Option exercise | +19,890 | $12.57 | $250K | 45,094 |
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −19,890 | $28.10 | $559K | 25,204 |
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Option exercise · Stock Option (Right to Buy) | −1,110 | 36,663 | ||
| 2018-01-16 | Dylan-Hyde Tyler Chief Legal Officer | Option exercise · Stock Option (Right to Buy) | −19,890 | 5,237 | ||
| 2018-01-05 | BAYER AKTIENGESELLSCHAFT 10% owner | Purchase | +527,472 | $22.75 | $12.0M | 5,632,802 |
Page 55 of 62 · 1,221 trades